Amorfix partners with reMYND to offer A4 amyloid testing services

Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).

"We are pleased to be working with reMYND to offer our A4 services to their clients, together providing a comprehensive solution to assess efficacy of drug candidates for treating AD using their proprietary models," said Vigen Nazarian, Vice President of Strategic Alliances for Amorfix. "This partnership is an important first step to accessing new clients as we build our AD services business."

"The Amorfix A4 assay has demonstrated its ability to detect beta-amyloid aggregates much earlier than other methods, hence giving our clients valuable information as to the effectiveness of their AD drugs in development," said Dr. An Tanghe, Contract Research Manager of reMYND. "The highly sensitive A4 assay detects aggregated Abeta in the brains of our Alzheimer transgenic mice before plaque formation, and thus coinciding with their early onset and clearly pre-plaque cognitive impairment. This is especially intriguing in the light of findings that soluble Abeta oligomers are significantly elevated in the brain of AD patients and correlate with cognitive decline."

Amorfix will be promoting the A4 assay at the International Convention on Alzheimer's Disease (ICAD) from July 10 - 15, 2010. Please visit us at Booth 816 for more information on the A4 technology and on reMYND's CRO services.